TapImmune Inc. (NASDAQ:MRKR) saw unusually-strong trading volume on Friday . Approximately 711,100 shares traded hands during mid-day trading, an increase of 54% from the previous session’s volume of 460,779 shares.The stock last traded at $5.90 and had previously closed at $5.81.
Several research analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of TapImmune in a research report on Wednesday, July 3rd. They issued an “outperform” rating and a $15.00 price objective on the stock. Zacks Investment Research cut shares of TapImmune from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. Roth Capital assumed coverage on shares of TapImmune in a research report on Thursday, May 30th. They issued a “buy” rating and a $10.00 price objective on the stock. ValuEngine cut shares of TapImmune from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. Finally, Janney Montgomery Scott restated a “buy” rating on shares of TapImmune in a research report on Sunday, July 21st. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $10.21.
The business has a fifty day simple moving average of $5.05 and a 200-day simple moving average of $5.96. The company has a quick ratio of 16.85, a current ratio of 16.85 and a debt-to-equity ratio of 0.01. The firm has a market cap of $269.46 million, a P/E ratio of -3.53 and a beta of 0.28.
TapImmune (NASDAQ:MRKR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. On average, sell-side analysts anticipate that TapImmune Inc. will post -0.51 EPS for the current fiscal year.
In related news, insider Peter L. Hoang purchased 10,000 shares of TapImmune stock in a transaction dated Wednesday, August 14th. The stock was purchased at an average cost of $4.62 per share, for a total transaction of $46,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 23.70% of the stock is currently owned by corporate insiders.
TapImmune Company Profile (NASDAQ:MRKR)
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.